ICMR Initiates Phase I Trial for Indigenous Kyasanur Forest Disease Vaccine
Key Insights
The Indian Council of Medical Research has successfully developed a two-dose adjuvanted inactivated vaccine for Kyasanur Forest Disease (search) and initiated Phase I human clinical trials following regulatory approval.
The indigenous vaccine, developed in collaboration with Indian Immunologicals Limited (search), targets a significant regional infectious disease affecting Western Ghats states including Karnataka, Tamil Nadu, Kerala, Goa, and Maharashtra.
Animal challenge and toxicity studies have been completed, with GLP-grade vaccine material manufactured and regulatory approval obtained from the Central Drugs Standard Control Organization (search).
The Indian Council of Medical Research (ICMR) has advanced to Phase I human clinical trials for a novel indigenous vaccine against Kyasanur Forest Disease (search) (KFD), marking a significant milestone in addressing a critical regional health challenge in India's Western Ghats region. The vaccine development initiative, undertaken in response to a request from the Karnataka state government, represents a collaborative effort between ICMR's National Institute of Virology and Indian Immunologicals Limited (search).
Vaccine Development and Design
The newly developed vaccine is formulated as a two-dose adjuvanted inactivated vaccine with doses administered 28 days apart. This fully indigenous vaccine has successfully completed comprehensive preclinical evaluation, including animal challenge studies and toxicity assessments. The development team has manufactured GLP-grade vaccine material, meeting stringent quality standards required for human clinical testing.
Clinical Trial Progression
Following approval from the Central Drugs Standard Control Organization (search) (CDSCO), the Phase I clinical trial has been initiated to evaluate the vaccine's safety profile in human subjects. The trial represents the first human testing phase for this indigenous KFD vaccine (search) candidate. If the Phase I trial demonstrates favorable safety and immunogenicity results, the development program will advance to subsequent clinical trial phases.
Disease Burden and Regional Impact
Kyasanur Forest Disease (search) poses a significant public health challenge as an important regional infectious disease affecting multiple states in the Western Ghats region, including Karnataka, Tamil Nadu, Kerala, Goa, and Maharashtra. The disease's regional concentration underscores the need for targeted vaccine development to address this specific health burden in affected communities.
Regulatory Pathway and Future Development
The vaccine development program follows established regulatory pathways, with CDSCO approval required for each clinical phase. Upon successful completion of Phase I trials demonstrating safety and immunogenic response, the development team will initiate further clinical trials. Final regulatory approval from CDSCO will be sought if the vaccine proves both safe and immunogenic throughout the clinical development process.
The Government of India has committed to providing continued support to state governments in addressing complex health challenges, with this vaccine development initiative exemplifying coordinated efforts between central research institutions and regional health needs.